Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis - 21/06/19
, Lars Erik Bryld, MD, PhD b, Lone Skov, MD, PhD, DMSc aAbstract |
Background |
Biologics targeting interleukin 17 are increasingly being used for treatment of moderate-to-severe psoriasis, but data on drug survival for these therapies remain scarce.
Objectives |
To investigate the drug survival of secukinumab and ixekizumab in a nationwide cohort of patients with psoriasis in Denmark.
Methods |
Using DERMBIO, we examined Danish patients receiving treatment with secukinumab or ixekizumab according to the standard in-label dosing. Kaplan-Meier plots were used to present survival curves.
Results |
In all, 368 and 62 patients received treatment with secukinumab and ixekizumab, respectively. In total, 40.7% and 12.9% of secukinumab- and ixekizumab-treated patients were bionaive. Ixekizumab-treated patients had received significantly more previous treatments. Over 12 months, 23.5% and 0.0% of bionaive secukinumab- and ixekizumab-treated patients discontinued therapy, respectively. Drug survival for bionaive and non-naive patients was lower for secukinumab than for ixekizumab. During the maximum 3 years of follow-up, secukinumab drug survival was lowest for patients who had previously been treated with 2 or more biologics, followed by patients treated with secukinumab as their second-ever biologic.
Limitations |
The total number of patients and follow-up time were modest.
Conclusions |
Drug survival was higher for ixekizumab even though secukinumab-treated patients had been treated with significantly fewer biologics before starting this drug.
Le texte complet de cet article est disponible en PDF.Key words : biologics, drug survival, IL-17, ixekizumab, psoriasis, secukinumab
Abbreviations used : IL, SD
Plan
| Funding sources: None. |
|
| Disclosure: Dr Egeberg has received research funding from Pfizer, Eli Lilly and Company, the Danish National Psoriasis Foundation, and the Kgl Hofbundtmager Aage Bang Foundation and honoraria as a consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Samsung Bioepis Co, Ltd, Pfizer, Eli Lilly and company, Novartis, Galderma, and Janssen Pharmaceuticals. Dr Skov has been a paid speaker for Pfizer, AbbVie, Eli Lilly and Company, Novartis, and LEO Pharma and has been a consultant or served on advisory boards with Pfizer, AbbVie, Janssen Cilag, Novartis, Eli Lilly and Company, LEO Pharma, and Sanofi. She has served as an investigator for Pfizer, AbbVie, Eli Lilly and Company, Novartis, Amgen, Regeneron, and LEO Pharma and received research and educational grants from Pfizer, AbbVie, Novartis, Sanofi, Janssen Cilag, and Leo Pharma. The authors do not have equity in pharmaceutical companies. |
|
| Dr Egeberg had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis, as well as for the study concept, design and drafting of the article, and statistical analysis. Drs Egeberg, Bryld, and Skov all take responsibility for acquisition, analysis, and interpretation of the data, as well as for critical revision of the article for important intellectual content. Drs Egeberg and Skov take responsibility for administrative, technical, or material support, as well as for study supervision. |
|
| Reprints not available from the authors. |
Vol 81 - N° 1
P. 173-178 - juillet 2019 Retour au numéro
Article précédent
- Sexual dysfunction in men taking systemic dermatologic medication: A systematic review
- George A. Zakhem, Julia E. Goldberg, Catherine C. Motosko, Brandon E. Cohen, Roger S. Ho
- Rituximab therapy in patients with bullous pemphigoid: A retrospective study of 20 patients
- Maxim Polansky, Rachel Eisenstadt, Taryn DeGrazia, Xiwen Zhao, Yuan Liu, Ron Feldman
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?